Operose Advisors LLC Sells 1,633 Shares of Johnson & Johnson (NYSE:JNJ)

Operose Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 33.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,321 shares of the company's stock after selling 1,633 shares during the quarter. Operose Advisors LLC's holdings in Johnson & Johnson were worth $480,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. United Capital Financial Advisors LLC boosted its position in shares of Johnson & Johnson by 10.1% in the fourth quarter. United Capital Financial Advisors LLC now owns 291,841 shares of the company's stock valued at $42,206,000 after acquiring an additional 26,674 shares during the period. Delaney Dennis R boosted its stake in Johnson & Johnson by 1.9% in the 4th quarter. Delaney Dennis R now owns 40,032 shares of the company's stock valued at $5,789,000 after buying an additional 730 shares in the last quarter. Gabelli Funds LLC grew its holdings in shares of Johnson & Johnson by 1.3% in the 4th quarter. Gabelli Funds LLC now owns 195,485 shares of the company's stock worth $28,271,000 after purchasing an additional 2,450 shares during the last quarter. Jump Financial LLC raised its stake in shares of Johnson & Johnson by 2,001.9% in the fourth quarter. Jump Financial LLC now owns 31,717 shares of the company's stock valued at $4,587,000 after acquiring an additional 30,208 shares during the last quarter. Finally, Anchor Investment Management LLC raised its position in Johnson & Johnson by 0.8% in the 4th quarter. Anchor Investment Management LLC now owns 91,625 shares of the company's stock valued at $13,251,000 after purchasing an additional 752 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $3.51 during trading hours on Friday, hitting $157.42. 10,972,370 shares of the company's stock traded hands, compared to its average volume of 7,953,112. The firm has a market cap of $379.37 billion, a P/E ratio of 23.67, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business's fifty day simple moving average is $159.49 and its two-hundred day simple moving average is $155.03. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.30%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is presently 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on JNJ shares. Barclays cut their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Raymond James dropped their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.